Topic

#avalo-therapeutics

1 story

Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3 (NASDAQ:AVTX)

Avalo Therapeutics presents a compelling contrarian buy opportunity following positive LOTUS trial results for abdakibart. The drug's monthly dosing schedule provides a distinct competitive edge in treating hidradenitis suppurativa.

1.5K488